Myeloid blast phase Philadelphia chromosome positive chronic myelocytic leukemia

Myeloid blast phase Philadelphia chromosome-positive chronic myelocytic leukemia represents the advanced, aggressive transformation of chronic myelocytic leukemia affecting the hematopoietic system

Myeloid blast phase Philadelphia chromosome-positive chronic myelocytic leukemia represents the advanced, aggressive transformation of chronic myelocytic leukemia affecting the hematopoietic system Patients commonly experience profound cytopenias, systemic constitutional symptoms, and rapidly progressive disease refractory to standard early-stage management

Driven by the reciprocal t(9;22)(q34;q11.2) translocation that generates the constitutively active BCR::ABL1 tyrosine kinase fusion gene, the disease is characterized by secondary genetic alterations and a failure of terminal differentiation

Driven by the reciprocal t(9;22)(q34;q11.2) translocation that generates the constitutively active BCR::ABL1 tyrosine kinase fusion gene, the disease is characterized by secondary genetic alterations and a failure of terminal differentiation

Clinically, it behaves analogously to acute myeloid leukemia and is defined by the presence of 20% or more myeloid blasts in the peripheral blood or bone marrow, or by the presence of extramedullary myeloid blast proliferations (myeloid sarcoma) Patients commonly experience profound cytopenias, systemic constitutional symptoms, and rapidly progressive disease refractory to standard early-stage management